Combination of palbociclib and letrozole shows promising results in first-line treatment of ER-positive, HER2-negative advanced breast cancer

A combination of palbociclib, a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6, and aromatase inhibitor letrozole demonstrated a statistically significant improvement in progression-free survival (PFS) in a phase II trial of first-line treatment for ER-positive, HER2-negative advanced breast cancer, according to Dr Richard Finn, an associate professor of medicine at the University of California, Los Angeles (UCLA). He presented the study results at AACR Annual Meeting 2014 (5-9 April, San Diego, USA). Read more here.